Frier Levitt partner Jesse Dresser is featured in Specialty Pharmacy Continuum’s article, “340B Discounts at Risk In 2025 and Beyond,” which examines the increasing legal and policy pressures threatening the future of the 340B Drug Pricing Program.
The article highlights how ongoing litigation, manufacturer restrictions, and reimbursement practices are placing 340B discounts under heightened scrutiny, drawing from Dresser’s presentation at the ASHP Pharmacy Futures 2025 Meeting in Charlotte, North Carolina. In discussing these challenges, Dresser emphasized a central legal issue facing covered entities and pharmacies, noting that “the common theme is that you can’t pay a pharmacy less just because it’s a 340B claim.”
As scrutiny of the 340B program intensifies heading into 2025, the article emphasizes the importance of proactive compliance strategies and experienced legal guidance to navigate an evolving regulatory landscape that could significantly impact patient access and provider operations.
Read the full article on Specialty Pharmacy Continuum to learn more about the risks facing the 340B program in 2025.
